Caribou Biosciences (CRBU) EBITDA (2020 - 2026)

Caribou Biosciences (CRBU) has 7 years of EBITDA data on file, last reported at -$26.3 million in Q1 2026.

• On a quarterly basis, EBITDA rose 38.76% year-over-year to -$26.3 million in Q1 2026; TTM through Mar 2026 was -$131.7 million, a 19.46% increase from a year earlier, with the FY2025 full-year figure at -$148.3 million, up 10.97% from the prior year.
• EBITDA for Q1 2026 stood at -$26.3 million, up from -$28.5 million in the prior quarter.
• Over the last five years, EBITDA for CRBU reached as high as -$14.6 million in Q3 2023 and fell as low as -$47.6 million in Q2 2025.
• Historically, EBITDA has averaged -$33.2 million across 5 years, with a median of -$31.1 million in 2023.
• Across the five-year window, EBITDA soared 44.86% in 2023 and plunged 161.31% in 2024, its largest moves.
• Year by year, EBITDA stood at -$30.6 million in 2022, then fell by 22.45% to -$37.4 million in 2023, then retreated by 3.83% to -$38.9 million in 2024, then increased by 26.81% to -$28.5 million in 2025, then advanced by 7.64% to -$26.3 million in 2026.
• Per Business Quant data, the three most recent EBITDA figures were -$26.3 million in Q1 2026, -$28.5 million in Q4 2025, and -$29.4 million in Q3 2025.